EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte Studie

Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study

Beatriz Borjabad, Jhon Rojas, Alexy Inciarte, Abiu Sempere, Ivan Chivite, Ana González-Cordón iD, Maria M Mosquera, Berta Torres iD, Julia Calvo, Lorena de la Mora, Maria Martinez-Rebollar, Montserrat Laguno und 9 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag040 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Beatriz Borjabad und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital Moises Broggi, Sant Joan Despí, Spain. Hauptthemen laut MEDLINE: Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Benzoxazines, Emtricitabine. Die Arbeit nennt 40 Literaturangaben. Gefördert von: CIBERINFEC, Instituto de Salud Carlos III, European Union-NextGenerationEU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Following a successful pilot study of a three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate, we hypothesized that this strategy would sustain virological efficacy and reduce long-term toxicities.

Methods

After a 24-week randomized phase, participants in the A-TRI-WEEK trial (ClinicalTrials.gov NCT01778413) were offered the three-day-per-week regimen. The extension was approved by the Institutional Review Board, and participants provided informed consent; follow-up continued until further participation no longer offered additional clinical or research value. HIV-RNA, CD4 and CD8 cells, blood and urine chemistries, and bone mineral density (BMD) were assessed every 6 months. Treatment failure was defined a priori as virological failure (HIV RNA >1000 copies/mL once or ≥50 copies/mL confirmed), discontinuation, or loss to follow-up. Secondary outcomes included changes in lipids, estimated glomerular filtration rate (eGFR), urine protein/creatinine, and BMD.

Results

Of 61 participants completing the 24-week phase, 59 (97%) entered the extension. After 7 years, 37 (63%) remained free of treatment failure. Only one participant experienced virological failure, following an unintentional treatment interruption, with no resistance mutations detected. All other failures were due to discontinuations (CNS symptoms, n = 7; BMD decline, n = 7; drug interactions, n = 2; regimen preference, n = 2; cancer, n = 1; death unrelated, n = 1; loss to follow-up, n = 1). Laboratory parameters showed biphasic patterns, with initial stability followed by modest late declines in eGFR and BMD and increases in triglycerides and proteinuria. Most discontinuations occurred in the latter half of follow-up (years 4–7).

Conclusions

A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV/TDF/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor–based regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveBenzoxazinesEmtricitabineHIV InfectionsTenofovirAdultFemaleHumansMaleMiddle AgedAlkynesCyclopropanesRNA, ViralTreatment OutcomeViral Load

Substanzen

AlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesefavirenzEmtricitabineRNA, ViralTenofovir

Autor:innen und Institutionen

  • Department of Internal Medicine, Hospital Moises Broggi, Sant Joan Despí, Spain.
  • Department of Infectious Diseases, Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain.
  • Department of Infectious Diseases, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Microbiology, Hospital Clínic-ISGLOBAL-, University of Barcelona, Barcelona, Spain.
  • Acquired Immunodeficiency Syndrome (AIDS) Immunopathology Unit, National Center for Microbiology, Institute of Health Carlos III, Majadahonda, Spain.

ORCID-Profile: Ana González-Cordón, Berta Torres, Alberto Foncillas, José M Miró, Elisa de Lazzari, Esteban Martinez

Förderung

  • CIBERINFEC
  • Instituto de Salud Carlos III
  • European Union-NextGenerationEU
  • European Regional Development Fund
  • Una manera de hacer Europa
  • European Union—NextGenerationEU

Zitieren

APA

Borjabad, B., Rojas, J., Inciarte, A., Sempere, A., Chivite, I., González-Cordón, A., Mosquera, M. M., Torres, B., Calvo, J., de la Mora, L., Martinez-Rebollar, M., Laguno, M., Foncillas, A., Ambrosioni, J., Alcami, J., Miró, J. M., Blanco, J. L., Sanchez-Palomino, S., Blanch, J., …, & Martinez, E. (2026). Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag040

Vancouver

Borjabad B, Rojas J, Inciarte A, Sempere A, Chivite I, González-Cordón A, et al. Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag040

BibTeX
@article{Borjabad2026,
  author = {Borjabad, Beatriz and Rojas, Jhon and Inciarte, Alexy and Sempere, Abiu and Chivite, Ivan and González-Cordón, Ana and Mosquera, Maria M and Torres, Berta and Calvo, Julia and de la Mora, Lorena and Martinez-Rebollar, Maria and Laguno, Montserrat and Foncillas, Alberto and Ambrosioni, Juan and Alcami, Jose and Miró, José M and Blanco, Jose L and Sanchez-Palomino, Sonsoles and Blanch, Jordi and de Lazzari, Elisa and Martinez, Esteban},
  title = {Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag040}
}
Kostenlos starten →